Afatinib and Temozolomide combination inhibits tumorigenesis by targeting EGFRvIII-cMet signaling in glioblastoma cells

BACKGROUND: Glioblastoma (GBM) is an aggressive brain tumor with universal recurrence and poor prognosis. The recurrence is largely driven by chemoradiation resistant cancer stem cells (CSCs). Epidermal growth factor receptor (EGFR) and its mutant EGFRvIII are amplified in ~ 60% and ~ 30% of GBM pat...

पूर्ण विवरण

में बचाया:
ग्रंथसूची विवरण
में प्रकाशित:J Exp Clin Cancer Res
मुख्य लेखकों: Vengoji, Raghupathy, Macha, Muzafar A., Nimmakayala, Rama Krishna, Rachagani, Satyanarayana, Siddiqui, Jawed A., Mallya, Kavita, Gorantla, Santhi, Jain, Maneesh, Ponnusamy, Moorthy P., Batra, Surinder K., Shonka, Nicole
स्वरूप: Artigo
भाषा:Inglês
प्रकाशित: BioMed Central 2019
विषय:
Research
ऑनलाइन पहुंच:https://ncbi.nlm.nih.gov/pmc/articles/PMC6582495/
https://ncbi.nlm.nih.gov/pubmed/31215502
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s13046-019-1264-2
टैग : टैग जोड़ें
कोई टैग नहीं, इस रिकॉर्ड को टैग करने वाले पहले व्यक्ति बनें!

समान संसाधन